AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22647826 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy
Number of subjects: 270
Study 22647826 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 270
Study 21875880 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 187
Study 21875880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 19356761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) training program for 16 weeks
Number of subjects: 40
Study 19356761 — intervention group
Group type: COMPARATOR
Intervention: Control group received general education for 16 weeks
Number of subjects: 40
Study 17357293 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Daily Insulin Injections (MDI)
Number of subjects: 90
Study 17357293 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII)
Number of subjects: 90
Study 17357293 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Intravenous Insulin Infusion (IVII)
Number of subjects: 90
Study 15243929 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (ACP)
Number of subjects: 200
Study 15243929 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ACP vaccine)
Number of subjects: 200
Study 11181931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine 0.2 mg/kg i.v.
Number of subjects: 34
Study 11181931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine 0.4 mg/kg i.v.
Number of subjects: 34
Study 11181931 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (both doses)
Number of subjects: 34
Study 9389848 — intervention group
Group type: EXPERIMENTAL
Intervention: NVHD-2
Number of subjects: 30
Study 9389848 — intervention group
Group type: EXPERIMENTAL
Intervention: NVHD-6
Number of subjects: 30
Study 9389848 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NVHD)
Number of subjects: 30
Study 8198906 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg
Number of subjects: 120
Study 8198906 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 1.25 mg
Number of subjects: 120
Study 8198906 — intervention group
Group type: COMPARATOR
Intervention: saline 0.9%
Number of subjects: 120
Study 2897558 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine sweatspot test (0.1 ml 1% acetylcholine administered intradermally)
Number of subjects: 24
Study 2897558 — intervention group
Group type: COMPARATOR
Intervention: Pupil test
Number of subjects: 24
Study 2897558 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular autonomic function tests
Number of subjects: 24
Study 30185575 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided Internet-based cognitive behaviour therapy (ICBT)
Number of subjects: 120
Study 26522083 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine/chemotherapy (arm-A)
Number of subjects: 214
Study 26522083 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (arm-B)
Number of subjects: 214
Study 25148170 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic steatosis patients (n = 71)
Number of subjects: 304
Study 25148170 — intervention group
Group type: COMPARATOR
Intervention: Patients without hepatic steatosis
Number of subjects: 304
Study 22213783 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent type with varying levels of control over data release decisions
Number of subjects: 0
Study 22213783 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up interview
Number of subjects: 0
Study 20923081 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to perfumes
Number of subjects: 0
Study 20923081 — intervention group
Group type: COMPARATOR
Intervention: No odors (control)
Number of subjects: 0
Study 18661059 — intervention group
Group type: COMPARATOR
Intervention: Routine surgical modality (Group 1)
Number of subjects: 110
Study 18661059 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserving the fascia parotideomasseterica and great auricular nerve with partial parotidectomy (Group 2)
Number of subjects: 110
Study 18661059 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (Routine surgical modality)
Number of subjects: 110
Study 18661059 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (Modified technique)
Number of subjects: 110
Study 18661059 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 16186270 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIP 2.6 mg
Number of subjects: 20
Study 16186270 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIP 5.2 mg
Number of subjects: 20
Study 16186270 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIP 7.8 mg
Number of subjects: 20
Study 16186270 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIP
Number of subjects: 20
Study 16186270 — intervention group
Group type: COMPARATOR
Intervention: SC lispro
Number of subjects: 20
Study 11489700 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 2 mg
Number of subjects: 272
Study 11489700 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg
Number of subjects: 272
Study 11489700 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 8 mg
Number of subjects: 272
Study 9566806 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dosing of buprenorphine (maintenance doses every 24 h)
Number of subjects: 17
Study 9566806 — intervention group
Group type: COMPARATOR
Intervention: Alternate-day dosing of buprenorphine (double maintenance doses every 48 h with placebo on intervening days)
Number of subjects: 17
Study 8070504 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional formulation of metoprolol (100 mg)
Number of subjects: 7
Study 8070504 — intervention group
Group type: COMPARATOR
Intervention: Sustained‐release formulation of metoprolol (100 mg)
Number of subjects: 7
Study 3135786 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (2 x 20 mg kg‐1)
Number of subjects: 111
Study 3135786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz (2 x 15 mg kg‐1)
Number of subjects: 111
Study 3135786 — intervention group
Group type: COMPARATOR
Intervention: Mass chemotherapy
Number of subjects: 111
Study 3135786 — intervention group
Group type: COMPARATOR
Intervention: Follow-up after treatment
Number of subjects: 111
Study 30911857 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb BVS oversized group
Number of subjects: 80
Study 30911857 — intervention group
Group type: COMPARATOR
Intervention: Absorb BVS non-oversized group
Number of subjects: 80
Study 30911857 — intervention group
Group type: EXPERIMENTAL
Intervention: Xience EES oversized group
Number of subjects: 80
Study 30911857 — intervention group
Group type: COMPARATOR
Intervention: Xience EES non-oversized group
Number of subjects: 80
Study 28583342 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin (100 mg/d)
Number of subjects: 745
Study 28583342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 745
Study 23299714 — intervention group
Group type: EXPERIMENTAL
Intervention: Kamut products (bread, pasta, and crackers)
Number of subjects: 22
Study 21295494 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day for 30 days, then 10 mg/day for 60 days
Number of subjects: 33
Study 21295494 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day to 10 mg/day
Number of subjects: 33
Study 21295494 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 33
Study 20606776 — intervention group
Group type: EXPERIMENTAL
Intervention: HESA-A (25 mg/Kg twice a day orally for 4 weeks)
Number of subjects: 280
Study 20606776 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same method as treatment for 4 weeks)
Number of subjects: 280
Study 16696414 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen suspension (3 doses given 24 hours apart)
Number of subjects: 42
Study 16696414 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 42
Study 15208824 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (Emend) in combination with standard antiemetic agents
Number of subjects: 0
Study 15208824 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic therapy
Number of subjects: 0
Study 11134441 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal heart rate characteristics (HRC)
Number of subjects: 89
Study 11134441 — intervention group
Group type: EXPERIMENTAL
Intervention: Score for Neonatal Acute Physiology (SNAP)
Number of subjects: 89
Study 11134441 — intervention group
Group type: EXPERIMENTAL
Intervention: Third moment (skewness) of heart rate characteristics
Number of subjects: 89
Study 11134441 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal Therapeutic Intervention Scoring System (NTISS)
Number of subjects: 89
Study 11134441 — intervention group
Group type: COMPARATOR
Intervention: Heart rate characteristics (HRC) and clinical scores
Number of subjects: 89
Study 9781529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 149
Study 9781529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 8143470 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 g/day of albumin until the circulating albumin concentration increased to > 3.0 g/dL (> 30 g/L)
Number of subjects: 219
Study 8143470 — intervention group
Group type: COMPARATOR
Intervention: No supplemental albumin
Number of subjects: 219
Study 2646246 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied 2% glycopyrrolate lotion/cream
Number of subjects: 61
Study 2646246 — intervention group
Group type: COMPARATOR
Intervention: Topically applied placebo
Number of subjects: 61
Study 31500854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer 0.8 g (low-dose)
Number of subjects: 72
Study 31500854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer 2.4 g (high-dose)
Number of subjects: 72
Study 31500854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 31500854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer (high-dose) in highest baseline phosphate quartile group
Number of subjects: 72
Study 28476766 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3234
Study 28476766 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 3234
Study 28476766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234
Study 25701101 — intervention group
Group type: EXPERIMENTAL
Intervention: Home‐based Post‐Hip Fracture Rehabilitation program (6 months)
Number of subjects: 232
Study 23539427 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of bisoprolol fumarate 5 mg and hydrochlorothiazide 6.25 mg
Number of subjects: 18
Study 21270370 — intervention group
Group type: EXPERIMENTAL
Intervention: Staggered meal consumption (2 hours with 3 within-meal pauses)
Number of subjects: 38
Study 21270370 — intervention group
Group type: COMPARATOR
Intervention: Nonstaggered meal consumption (0.5 hours)
Number of subjects: 38
Study 19697824 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose of 1 microg kg(‐1) over 10 min, followed by 0.2 microg kg(‐1) h(‐1) continuous infusion)
Number of subjects: 64
Study 19697824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 16537185 — intervention group
Group type: EXPERIMENTAL
Intervention: Single epirubicin (80 mg/40 mL of normal saline) administered into the bladder within 6 hours postoperation
Number of subjects: 47
Study 16537185 — intervention group
Group type: COMPARATOR
Intervention: 40 mg Epirubicin consecutively, instillation every week for 6-8 weeks and then every one month for 10 months
Number of subjects: 47
Study 16537185 — intervention group
Group type: COMPARATOR
Intervention: 40 mg mitomycin C, consecutively, instillation every week for 6-8 weeks and then every one month for 10 months
Number of subjects: 47
Study 16167266 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative brace set at full extension (group A)
Number of subjects: 46
Study 16167266 — intervention group
Group type: COMPARATOR
Intervention: Postoperative brace set at flexion of 20 degrees (group B)
Number of subjects: 46
Study 12962937 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole
Number of subjects: 102
Study 12962937 — intervention group
Group type: COMPARATOR
Intervention: Vaginal metronidazole
Number of subjects: 102
Study 10436093 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver Strain Index measurement at 1, 3, and 6 months after stroke
Number of subjects: 0
Study 10436093 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke severity indicator
Number of subjects: 0
Study 8526836 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermeasures (CM) including regular muscular exercise and LBNP sessions (‐30 mm Hg)
Number of subjects: 12
Study 8526836 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 12
Study 8526836 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermeasures (CM)
Number of subjects: 12
Study 8526836 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CM and C)
Number of subjects: 12
Study 2487539 — intervention group
Group type: EXPERIMENTAL
Intervention: tiapamil 450 mg b.i.d.
Number of subjects: 81
Study 2487539 — intervention group
Group type: COMPARATOR
Intervention: atenolol 100 mg daily
Number of subjects: 81
Study 322529 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of vitamin C
Number of subjects: 53
Study 322529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 31404668 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg
Number of subjects: 1758
Study 31404668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1758
Study 28450898 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses and prescribed motion control shoes
Number of subjects: 44
Study 28450898 — intervention group
Group type: COMPARATOR
Intervention: Prescribed motion control shoes alone
Number of subjects: 44
Study 25974287 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (titrated to a median of 50 mg, interquartile range 25-50 mg)
Number of subjects: 124
Study 25974287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 27053951 — intervention group
Group type: EXPERIMENTAL
Intervention: TS audiometer
Number of subjects: 60
Study 27053951 — intervention group
Group type: COMPARATOR
Intervention: Conventional audiometer
Number of subjects: 60
Study 21845239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting
Number of subjects: 40
Study 21845239 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribochemical silica coating
Number of subjects: 40
Study 21845239 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribochemical silica coating + silanization
Number of subjects: 40
Study 21845239 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 19234425 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions over 5 weeks)
Number of subjects: 8
Study 16317318 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-feedback therapy (bimonthly sessions)
Number of subjects: 30
Study 16317318 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling (control group)
Number of subjects: 30
Study 12725603 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with omeprazole, clarithromycin, and tinidazole for 7 days followed by omeprazole for 21 days
Number of subjects: 103
Study 12725603 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with omeprazole, clarithromycin, and tinidazole for 7 days followed by placebo for 21 days
Number of subjects: 103
Study 12725603 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (after 16 weeks)
Number of subjects: 103
Study 10950759 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C rotavirus infection
Number of subjects: 0
Study 10950759 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C rotavirus strains
Number of subjects: 0
Study 9165933 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile only (T)
Number of subjects: 54
Study 9165933 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory, tactile and visual (ATV)
Number of subjects: 54
Study 9165933 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory, tactile, visual and vestibular (ATVV)
Number of subjects: 54
Study 9165933 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory only (A)
Number of subjects: 54
Study 9165933 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 54
Study 8259721 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ) 200 mg daily and placebo
Number of subjects: 40
Study 8259721 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) and Methotrexate (MTX) 7.5 mg once a week
Number of subjects: 40
Study 3916621 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer assisted conventional insulin therapy
Number of subjects: 17
Study 29807740 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation method
Number of subjects: 21
Study 29807740 — intervention group
Group type: COMPARATOR
Intervention: Library method
Number of subjects: 21
Study 28228182 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodGYM (free-to-use cCBT programme)
Number of subjects: 0
Study 28228182 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating the Blues (commercial cCBT programme)
Number of subjects: 0
Study 28228182 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care alone
Number of subjects: 0
Study 26175297 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (four sessions with one week interval)
Number of subjects: 90
Study 26175297 — intervention group
Group type: COMPARATOR
Intervention: Routine program offered by the center (control group)
Number of subjects: 90
Study 23441790 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% azithromycin (AZM)
Number of subjects: 54
Study 23441790 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 54
Study 21995887 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge formula (PDF; n=52, 0.4% DHA, 0.4% AA)
Number of subjects: 139
Study 21995887 — intervention group
Group type: COMPARATOR
Intervention: Term formula (TF; n=41, 0.2% DHA, 0.2% AA)
Number of subjects: 139
Study 21995887 — intervention group
Group type: COMPARATOR
Intervention: Human milk (HM; n=46)
Number of subjects: 139
Study 18164104 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario-based simulation training
Number of subjects: 141
Study 18164104 — intervention group
Group type: COMPARATOR
Intervention: Scenario-based study groups with teacher
Number of subjects: 141
Study 18164104 — intervention group
Group type: COMPARATOR
Intervention: Scenario-based study groups without teacher
Number of subjects: 141
Study 16829083 — intervention group
Group type: EXPERIMENTAL
Intervention: On-CPB with cell saver blood transfusion (CSBT)
Number of subjects: 80
Study 16829083 — intervention group
Group type: COMPARATOR
Intervention: On-CPB without CSBT
Number of subjects: 80
Study 16829083 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump with CSBT
Number of subjects: 80
Study 16829083 — intervention group
Group type: COMPARATOR
Intervention: Off-pump without CSBT
Number of subjects: 80
Study 16829083 — intervention group
Group type: COMPARATOR
Intervention: On-CPB (both with and without CSBT)
Number of subjects: 80
Study 16829083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell saver groups (A and C)
Number of subjects: 80
Study 16829083 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 12949925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavior therapy
Number of subjects: 125
Study 11729513 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN + FDP (1 g/kg daily for dogs; 5 g, two times a day for patients)
Number of subjects: 29
Study 11729513 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN + FDP
Number of subjects: 29
Study 11729513 — intervention group
Group type: COMPARATOR
Intervention: Routine TPN (control group for clinical study)
Number of subjects: 29
Study 9605271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 884
Study 9605271 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 884
Study 8156344 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical systematic lymphadenectomy
Number of subjects: 182
Study 8156344 — intervention group
Group type: COMPARATOR
Intervention: Conventional node dissection
Number of subjects: 182
Study 3419826 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclopentolate HCl 1%
Number of subjects: 10
Study 3419826 — intervention group
Group type: EXPERIMENTAL
Intervention: phenylephrine HCl 10%
Number of subjects: 10
Study 3419826 — intervention group
Group type: COMPARATOR
Intervention: saline 0.9%
Number of subjects: 10
Study 31644793 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app care (IBDsmart and IBDoc)
Number of subjects: 100
Study 31644793 — intervention group
Group type: COMPARATOR
Intervention: Standard face-to-face care
Number of subjects: 100
Study 31079530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction (9 slow sodium tablets daily for 6 weeks)
Number of subjects: 64
Study 31079530 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo tablets daily for 6 weeks)
Number of subjects: 64
Study 28248624 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive website intervention
Number of subjects: 3
Study 28248624 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 26387142 — intervention group
Group type: EXPERIMENTAL
Intervention: THP (docetaxel with trastuzumab and pertuzumab)
Number of subjects: 350
Study 26387142 — intervention group
Group type: EXPERIMENTAL
Intervention: TH/TP/HP (docetaxel with trastuzumab, pertuzumab, or both)
Number of subjects: 350
Study 26387142 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab/chemotherapy (from NOAH trial)
Number of subjects: 350
Study 26387142 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (from NOAH trial)
Number of subjects: 350
Study 23942540 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM) plus AED strong inducers (carbamazepine, phenobarbital, phenytoin), n = 33
Number of subjects: 75
Study 21673612 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain polysaccharide vaccine (MenC-PS group, n=150)
Number of subjects: 543